CN103977089A - Compound medicine containing radix paeoniae rubrathe and phosphonomycin used for livestock and poultry - Google Patents
Compound medicine containing radix paeoniae rubrathe and phosphonomycin used for livestock and poultry Download PDFInfo
- Publication number
- CN103977089A CN103977089A CN201410202869.4A CN201410202869A CN103977089A CN 103977089 A CN103977089 A CN 103977089A CN 201410202869 A CN201410202869 A CN 201410202869A CN 103977089 A CN103977089 A CN 103977089A
- Authority
- CN
- China
- Prior art keywords
- medicine
- radix paeoniae
- poultry
- antimicrobial
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Fodder In General (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a compound medicine containing radix paeoniae rubrathe and phosphonomycin used for livestock and poultry. Raw materials of the compound medicine comprise, by weight, 3-30 parts of the phosphonomycin and 5-200 parts of the radix paeoniae rubrathe. The inventor employs a traditional Chinese medicine, radix paeoniae rubrathe, and an antimicrobial medicine to prepare the compound medicine. According to a research result, drug resistance of bacteria to the antimicrobial medicine can be inverted since the radix paeoniae rubrathe is added to the antimicrobial medicine, so that treatment effect of the antimicrobial medicine is improved. The compound medicine, which is manufactured into a powder, a tablet, an oral liquid or a particulate agent through to a conventional method, is added to livestock and poultry feed for feeding the livestock and poultry with an addition amount being 0.1-7g of a main drug per kilogram of feed. Medicine cost and medicine residue can be reduced greatly, breeding farmers obtain a higher economic benefit and meanwhile foodstuff safety is ensured.
Description
Technical field
The invention belongs to poultry escherichia coli and Salmonella infection treatment technology field, relate in particular to a kind of poultry compound medicine that contains Radix Paeoniae Rubra and fosfomycin.
Background technology
Fowl salmonellosis (Avian salmonellosis) is the general name of the caused poultry disease of one or more Salmonellas in Salmonella.According to the difference of pathogen antigen structure, can be divided into 3 classes: Pullorum Disease, avian typhoid and avian paratyphoid.Wherein Pullorum Disease and avian typhoid Salmonella have host specificity, mainly cause chicken and turkey morbidity; Avian paratyphoid Salmonella can extensively infect many animals and people, and poultry that is subject to its pollution and products thereof is one of main source of mankind's Salmonella infection and alimentary toxicosis.The propagation circulation that the normal formation of fowl salmonellosis is quite complicated.Sick fowl and the fowl that carries disease germs are the main sources of infection, can pass through digestive tract, respiratory tract or eye conjunctiva horizontal transmission, after ovum vertical transmission, can infect poult, cause most of death, poultry carries disease germs for a long time, the ovum that then output is carried disease germs, if using, this hatches as hatching egg, that can go round and begin again is handed down from age to age, and causes fowl salmonellosis in chicken group, to be difficult to purify, and causes serious economic loss.Because Salmonella pollution face in chicken group is large, and easily produce drug resistance, immune effect of vaccine is in the market all undesirable.Therefore, breeder flock quarantine, medicine are controlled, environment disinfected purifies, strengthen feeding and management and health and epidemic prevention is still control and prevents that Salmonella from entering the essential measure of food chain.Chickling goes out to drink 0.01% potassium permanganate solution after shell or other drug carries out chemoprophylaxis for 1～2 day.This bacterium produces drug resistance to common drug, forces in production, to have to carry out various medicines and be used alternatingly, in the hope of better controlling fastbacteria.This bacterium produces stronger drug resistance to aminoglycoside medicaments at present, and aminoglycoside inactive enzyme is that the necessary group of some protection antibacterial activity in these antibacterials molecules is modified, and itself and the ribosomal affinity of target site are greatly reduced.These inactive enzymes comprise aminoglycoside acyltransferase (AAC), aminoglycoside adenylyl transferase (AAD), aminoglycoside phosphotransferase (APH), gland nucleotidyltransferase (ANT) etc.In the fastbacteria of many aminoglycosides, found at present the inactive enzyme of different qualities.
Escherichia coli are common conditioned pathogens, also be normal a kind of disease of sending out, its multiple location severe infections such as chicken acute sepsis, peritonitis, hepatitis, pneumonia, enteritis of can formerly having carried out the coffin upon burial, also can secondary or mixed sending out in virosis, to aquaculture, causes huge economic loss.The beta-lactam lopps antibiotic such as amoxicillin, ampicillin, ceftiofur, ceftriaxone, amoxicillin/clavulanate, ampicillin/sulbactam are the conventional important drugs of this disease of control, along with cultivation scale intensive degree is more and more large, medication is more and more spread unchecked, its Resistant strain is more and more many, also more about the report of Drug Resistance of E. coli.Studies confirm that, one of main mechanism of drug resistance is to produce beta-lactamase, especially extended spectrumβ-lactamase (Extended-Spectrum β-lactamase, ESBLs), this enzyme can be more by force and is hydrolyzed rapidly beta-lactam nucleus, makes this class antibiotic lose antibacterial activity.ESBLs is the main enzyme type of beta-lactamase, and it is not only to cephalo three generations and aztreonam drug resistance, and aminoglycoside, quinolones and sulfonamides are to crossing drug resistant, only to carbapenems, a mould alkene class medicaments insensitive.Many documents have reported colibacillary multi-drug resistant and have produced ESBLs and have substantial connection, both at home and abroad to comparatively pay close attention to.The detection, extraction, enzyme that inventor has carried out food animal source pathogenic bacterium ESBLs recently presses down the researchs such as enzyme protection effect to antibiotic percent hydrolysis and sulbactam, Tazobactam Sodium and Chinese medicine; to part ESBLs, colibacillary drug sensitive test shows, its multidrug resistant rate is apparently higher than non-ESBLs bacterial strain.In addition, result also shows to produce ESBLs bacterial strain not only to the serious drug resistance of the third generation cephalosporins such as ceftiofur, and also to multiple antimicrobial drug drug resistance such as fluoroquinolones, aminoglycoside and sulfonamides, fosfomycin etc., is serious multidrug resistant.Inventor is separated to the escherichia coli that tolerate P-levels mycin produces fosA3 drug resistant gene in producing ESBLs bacterial strain, has more strengthened the drug resistance of antibacterial.
Salmonella and colibacillary drug resistance cause raiser's drug cost to increase, and treatment extends the course for the treatment of, and mortality of livestock increases, and to production, brings larger economic loss, and increase poultry drug residue risk.Therefore, in actual production, need badly a kind of to no matter whether the Salmonella of drug resistance and the medicine that escherichia coli can have better therapeutical effect, and can shorten and treat the course for the treatment of, reduce mortality rate, reduce economic loss and reduce drug residue, for raiser creates higher economic benefit, also ensure that the mankind's is healthy and safe.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of poultry compound medicine that contains Radix Paeoniae Rubra and fosfomycin, it can kill antibacterial quickly, overcome antimicrobial drug treatment due to large, the residual height of weak curative effect, consumption and the high defect of cost that drug resistance problem causes, avoided that simple Chinese medicine sterilizing spectrum is narrow, slow problem sterilizes.
For solving above technical problem, the present invention by the following technical solutions: a kind of poultry compound medicine that contains Radix Paeoniae Rubra and fosfomycin, is comprised of the raw material of following weight portion: fosfomycin 3-30 part, Radix Paeoniae Rubra 5-200 part.
Described compound medicine is prepared into powder, tablet, oral liquid or granule.
The preparation method of described compound medicine is: Radix Paeoniae Rubra was pulverized to 60 mesh sieves, then mix with pulverous antimicrobial drug, and be prepared into according to a conventional method powder, tablet, oral liquid or granule.
For the drug resistance problem of current poultry escherichia coli and Salmonella infection existence, inventor utilizes Lactiflora and antimicrobial drug to form compound medicine.Studies have shown that, in antimicrobial drug, add after Radix Paeoniae Rubra, can reverse the drug resistance of bacteria medicine, thereby improve the therapeutic effect of antimicrobial drug.According to a conventional method this compound medicine is made to powder, tablet, oral liquid or granule, according to the addition of 0.1-7g principal agent/kg feedstuff, add in animal and fowl fodder and feed, can significantly reduce drug cost and drug residue, for raiser creates higher economic benefit, also guaranteed food safety simultaneously.
The specific embodiment
One, the drug resistance inversion effect research of Radix Paeoniae Rubra to antimicrobial drug
Antimicrobial drug itself has the effect for the treatment of escherichia coli and Salmonella, but has stronger drug resistance owing to producing escherichia coli and the Salmonella of drug resistant gene, causes antimicrobial drug not show good therapeutic effect in normal using dosage situation.
1, Radix Paeoniae Rubra mix with antimicrobial drug after to colibacillary drug resistance inhibition test
On 96 orifice plates, adopt microtest tube doubling dilution, first measure antimicrobial drug to producing minimal inhibitory concentration and the subinhibitory concentration of Radix Paeoniae Rubra to product ESBLs and fosA3 drug resistant gene e. coli strains of the e. coli strains of ESBLs and fosA3 drug resistant gene, then in culture medium, added the Radix Paeoniae Rubra of subinhibitory concentration to reuse the minimal inhibitory concentration that microtest tube doubling dilution is cultivated mensuration antimicrobial drug; Utilize continuous passage method in the culture medium that is added with same subinhibitory concentration Radix Paeoniae Rubra and same concentration antimicrobial drug to producing the cultivation of going down to posterity of ESBLs and fosA3 drug resistant gene e. coli strains, until the antimicrobial drug minimal inhibitory concentration observing with go down to posterity before compare and diminish more than 4 times, can be judged as Radix Paeoniae Rubra has drug resistance inversion effect to antibacterial medical instrument.Result of the test statistics is as shown in table 1:
Table 1 subinhibitory concentration (0.5g/mL) Radix Paeoniae Rubra goes down to posterity and causes the variation (mg/mL) of producing ESBLs and fosA3 escherichia coli Western medicine MIC.
As seen from the above table, antimicrobial drug all reduces more than 4 times the colibacillary minimal inhibitory concentration of drug resistance, can judge that Radix Paeoniae Rubra has drug resistance inversion effect to producing ESBLs and fosA3 drug resistant gene escherichia coli.
2, Radix Paeoniae Rubra mix with antimicrobial drug after drug resistance inhibition test to Salmonella
On 96 orifice plates, adopt microtest tube doubling dilution, first measured antimicrobial drug to the minimal inhibitory concentration of drug resistance salmonella strain and Radix Paeoniae Rubra the subinhibitory concentration to drug resistance salmonella strain, then in culture medium, add the Radix Paeoniae Rubra of subinhibitory concentration to reuse microtest tube doubling dilution and cultivate the minimal inhibitory concentration of measuring antimicrobial drug; Utilize continuous passage method in the culture medium that is added with same subinhibitory concentration Radix Paeoniae Rubra and same concentration antimicrobial drug to the cultivation of going down to posterity of Salmonella persister, until the antimicrobial drug minimal inhibitory concentration observing with go down to posterity before compare and diminish more than 4 times, can be judged as Radix Paeoniae Rubra has drug resistance inversion effect to antibacterial medical instrument.Result of the test statistics is as shown in table 2:
Table 2 subinhibitory concentration (0.5g/mL) Radix Paeoniae Rubra goes down to posterity and causes the variation (mg/mL) of drug resistance Salmonella Western medicine MIC.
As seen from the above table, antimicrobial drug all reduces more than 4 times the minimal inhibitory concentration of drug resistance Salmonella, can judge that Radix Paeoniae Rubra has drug resistance inversion effect to drug resistance Salmonella.
Two, the application example of compound medicine of the present invention
According to table 3 formula and following methods Preparation Example 1-embodiment 4: Radix Paeoniae Rubra was pulverized after 60 mesh sieves, as basic material, then with pulverous antimicrobial drug by weight ratio put into blender and mix, compound medicine is prepared into formulation products.
The formula of table 3 embodiment 1-4 and preparation dosage form
| Numbering | Antimicrobial drug | Radix Paeoniae Rubra | Dosage form |
| Embodiment 1 | Fosfomycin 18g | 130g | Powder |
| Embodiment 2 | Fosfomycin 3g | 50g | Tablet |
| Embodiment 3 | Fosfomycin 9g | 10g | Oral liquid |
| Embodiment 4 | Fosfomycin 30g | 170g | Granule |
1, the compound medicine product of embodiment 1-4 gained carries out efficacy experiment to the meat-type duck diarrhoea of duck field, Nanning 30 ages in days.
Clinical symptoms: duck group draws watery stools, has obvious indigested feedstuff in feces.Indivedual serious duck appearance feet gradually of suffering from diarrhoea are soft slowly dead.
Cut open inspection pathological changes: the duck that dies of illness dehydration is more serious, indivedual ducks are still very large, duck liver enlargement, hyperemia, and adularescent film on the liver of part duck, air bag is muddy, and tentative diagnosis is escherichia coli or duck oromeningitis.
Test therapeutic regimen: morbidity duck group divides six groups of administrations, use embodiment 1 according to the addition administration of 0.8g/kg feedstuff for first group, use embodiment 2 according to the addition administration of 1.8g/kg feedstuff for second group, use embodiment 3 according to the addition administration of 2g/kg feedstuff for the 3rd group, use embodiment 4 according to the addition administration of 0.65g/kg feedstuff for the 4th group; The 5th group with fosfomycin powder according to the addition administration of 0.1g/kg feedstuff, the 6th group with the thick powder of Radix Paeoniae Rubra according to the addition administration of 4g/kg feedstuff; Above six groups of therapeutic regimens all continue to use 5 days.
Result of use feedback: first group to the 4th group medication is after 3 days, and sick duck is no longer drawn watery stools, feces is shaped, and no longer occurs dead duck, continues to use 2 days, and duck group be almost recovered; The 5th group of medication is after 3 days, duck group DeGrain, much still draw watery stools, contain indigested feedstuff, continue to use 2 days, some improvement a little, but thoroughly not good, rare watery stools still occurs, raiser uses the compound medicine of embodiment 1 gained instead, continue to use 3 days, feces all transfers to normally; The 6th group of medication is after 3 days, and duck does not have too large remarkable improvement, continues to use 2 days, and the duck phenomena of mortality are not still effectively controlled.Visible, the compound medicine that contains Radix Paeoniae Rubra is better than folk prescription to the curative effect of duck diarrhoea.
2, the efficacy experiment of embodiment 1-4 gained compound medicine product to Salmonella gallinarum disease.
Clinical symptoms: Nanning chicken house, 14 age in days laying hens, there is dysentery in chicken group, row white, pasty state loose stool, perianal tomentum fecal pollution, has Calx sample lump, and what have sends painful shriek, has the phenomena of mortality.Cut open the indivedual Hepar Gallus domesticus enlargements of inspection and be kermesinus to darkviolet, or khaki slightly, matter is crisp easily broken, and surface is dispersed in or greyish white, the downright bad point of lark that gathers, and be red petechia sometimes, typically Salmonella genius morbi.
Laboratory diagnosis: get pathologic liver and dye sheet, Gram’s staining, micro-Microscopic observation, the gram negative bacilli of red color visible; Tentatively be judged as Salmonella disease.By Salmonella, cultivate, biochemical test is differentiated, judges that chicken infects for Salmonella disease, and drug sensitive test result is judged as persister Salmonella according to NCCLS standard.
Test therapeutic regimen: morbidity chicken group is divided into 6 groups of administrations, use embodiment 1 according to the addition administration of 0.8g/kg feedstuff for first group, use embodiment 2 according to the addition administration of 1.8g/kg feedstuff for second group, use embodiment 3 according to the addition administration of 2g/kg feedstuff for the 3rd group, use embodiment 4 according to the addition administration of 0.65g/kg feedstuff for the 4th group; The 5th group with fosfomycin powder according to the addition administration of 0.1g/kg feedstuff, the 6th group with the thick powder of Radix Paeoniae Rubra according to the addition administration of 4g/kg feedstuff; Above six groups of therapeutic regimens all continue to use 5 days.
Effect feedback: after the chicken group medication of first group to the 4th group, sick chicken feed intake rises, and no longer occurs dead chicken, continues to use 3 days, and chicken group be almost recovered; The chicken group medication of the 5th group is after 2 days, and chicken group majority is still unhealthy, still has indivedual chicken deaths, continues to use 3 days, and chicken death phenomenon is not still effectively controlled; The chicken group medication of the 6th group is after 2 days, and chicken group does not have too large remarkable improvement, continues to use 3 days, and chicken death phenomenon is not still effectively controlled.Visible, the compound medicine curative effect that contains Radix Paeoniae Rubra is better than folk prescription.
Claims (2)
1. a poultry compound medicine that contains Radix Paeoniae Rubra and fosfomycin, is characterized in that, consists of: fosfomycin 3-30 part, Radix Paeoniae Rubra 5-200 part the raw material of following weight portion.
2. the poultry compound medicine that contains Radix Paeoniae Rubra and fosfomycin according to claim 1, is characterized in that, described compound medicine is prepared into powder, tablet, oral liquid or granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410202869.4A CN103977089B (en) | 2014-05-14 | 2014-05-14 | A kind of poultry compound medicine containing Radix Paeoniae Rubra and fosfomycin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410202869.4A CN103977089B (en) | 2014-05-14 | 2014-05-14 | A kind of poultry compound medicine containing Radix Paeoniae Rubra and fosfomycin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103977089A true CN103977089A (en) | 2014-08-13 |
| CN103977089B CN103977089B (en) | 2017-01-04 |
Family
ID=51269416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410202869.4A Active CN103977089B (en) | 2014-05-14 | 2014-05-14 | A kind of poultry compound medicine containing Radix Paeoniae Rubra and fosfomycin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103977089B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106109547A (en) * | 2016-08-22 | 2016-11-16 | 广西大学 | A kind of poultry compound medicine containing Herba Euphorbiae Humifusae and fosfomycin |
| CN106166176A (en) * | 2016-08-22 | 2016-11-30 | 广西大学 | A kind of poultry compound medicine containing Cortex Cinnamomi and fosfomycin |
| CN106176910A (en) * | 2016-08-22 | 2016-12-07 | 广西大学 | A kind of poultry compound medicine containing Radix Glycyrrhizae and fosfomycin |
| CN106309535A (en) * | 2016-08-29 | 2017-01-11 | 广西大学 | Compound medicine containing triquetrous tadehagi herbs and fosfomycin and used for livestock |
| CN106420903A (en) * | 2016-11-24 | 2017-02-22 | 防城港市畜牧站 | Compound pharmaceutical composition for poultry |
| CN106727818A (en) * | 2016-11-24 | 2017-05-31 | 防城港市畜牧站 | A kind of compound medicament composition for improving poultry disease resistance |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101002854A (en) * | 2007-02-05 | 2007-07-25 | 唐松 | Medicine containing clindamycin for treating acne |
| CN102247493A (en) * | 2011-07-07 | 2011-11-23 | 河北工程大学 | Chinese medicinal oral liquid capable of eliminating medicine resistance plasmid in chicken bacteria |
-
2014
- 2014-05-14 CN CN201410202869.4A patent/CN103977089B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101002854A (en) * | 2007-02-05 | 2007-07-25 | 唐松 | Medicine containing clindamycin for treating acne |
| CN102247493A (en) * | 2011-07-07 | 2011-11-23 | 河北工程大学 | Chinese medicinal oral liquid capable of eliminating medicine resistance plasmid in chicken bacteria |
Non-Patent Citations (1)
| Title |
|---|
| 张芳等: "赤芍提取物体外抑菌活性的研究", 《徐州医学院学报》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106109547A (en) * | 2016-08-22 | 2016-11-16 | 广西大学 | A kind of poultry compound medicine containing Herba Euphorbiae Humifusae and fosfomycin |
| CN106166176A (en) * | 2016-08-22 | 2016-11-30 | 广西大学 | A kind of poultry compound medicine containing Cortex Cinnamomi and fosfomycin |
| CN106176910A (en) * | 2016-08-22 | 2016-12-07 | 广西大学 | A kind of poultry compound medicine containing Radix Glycyrrhizae and fosfomycin |
| CN106309535A (en) * | 2016-08-29 | 2017-01-11 | 广西大学 | Compound medicine containing triquetrous tadehagi herbs and fosfomycin and used for livestock |
| CN106420903A (en) * | 2016-11-24 | 2017-02-22 | 防城港市畜牧站 | Compound pharmaceutical composition for poultry |
| CN106727818A (en) * | 2016-11-24 | 2017-05-31 | 防城港市畜牧站 | A kind of compound medicament composition for improving poultry disease resistance |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103977089B (en) | 2017-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103948930B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and beta-lactam antimicrobial drug | |
| CN103989728B (en) | It is a kind of to contain the livestock and poultry compound medicine containing pearl grass and beta-lactam class antimicrobial | |
| CN103977090B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and florfenicol | |
| CN103961421A (en) | Compound medicine containing radix paeoniae rubra and mequindox for livestock and poultry | |
| CN103977089B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and fosfomycin | |
| CN103989725A (en) | Acalypha australis L. and amikacin containing compound medicine for livestock and poultry | |
| CN103690952A (en) | Compound drug for treating livestock and poultry escherichia coli infected diseases | |
| CN103989729A (en) | Acalypha australis L. and sulfamonomethoxine sodium containing compound medicine for livestock and poultry | |
| CN103933086A (en) | Creat/amikacin-containing compound medicine for livestock and fowl | |
| CN103989731A (en) | Acalypha australis L. and florfenicol containing compound medicine for livestock and poultry | |
| CN103989727A (en) | Acalypha australis L. and mequindox containing compound medicine for livestock and poultry | |
| CN103948691B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and sulfamonomethoxine sodium | |
| CN103948692B (en) | A kind of livestock and poultry compound medicine containing the radix paeoniae rubrathe and amikacin | |
| CN104306420A (en) | Balsamiferou blumea herb and sulfamonomethoxine sodium containing compound medicine for livestock and poultry | |
| CN103989726A (en) | Acalypha australis L. and fosfomycin containing compound medicine for livestock and poultry | |
| CN103948656A (en) | Creat/fosfomycin-containing compound medicine for livestock and fowl | |
| CN103977088A (en) | Compound medicine containing radix paeoniae rubrathe and fluoroquinolones antibacterial drug used for livestock and poultry | |
| CN104337847B (en) | A kind of livestock and poultry compound medicine containing phoenix-tail fern and phosphonomycin | |
| CN104435012A (en) | Pteris multifida and florfenicol-containing compound drug for livestock and poultry | |
| CN104367601A (en) | Compound medicine containing herba pteridis multifidae and mequindox for livestock and poultry | |
| CN103908670B (en) | A kind of compound treating poultry coli-infection disease | |
| CN103933543A (en) | Method for treating Escherichia coli infection diseases by using creat and colimycin | |
| CN103933544A (en) | Creat/colimycin-containing compound medicine for livestock and fowl | |
| CN104306422A (en) | Balsamiferou Blumea herb and beta-lactam antibacterial drug containing compound medicine for livestock and poultry | |
| CN104435038A (en) | Balsamiferou blumea herb and mequindox containing compound medicine for livestock and poultry |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |